UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3592-3596

  Haaland, Richard E ^a   Evans Strickfaden, Tammy ^a   Holder, Angela ^a   Pau, Chou Pong ^a   McNicholl, Janet M ^a,b   Chaikummao, Supraporn ^b   Chonwattana, Wannee ^b   Hart, Clyde E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Centers for Disease Control CDC Thailand Field Station   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG ACTIVITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VAGINA DISCHARGE;

ADOLESCENT; ADULT; ANILIDES; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; BODY FLUIDS; FEMALE; FURANS; HUMANS; MIDDLE AGED; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 84862580084     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00452-12     Document Type: Article

References (31)

1. Abdool Karim Q, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
2. Anton PA, et al. 2011. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One 6:e23243. doi:10.1371/journal.pone.0023243.
3. Balzarini J, Brouwer WG, Dao DC, Osika EM, De Clercq E. 1996. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 40:1454-1466.
4. Balzarini J, De Clercq E, Carbonez A, Burt V, Kleim JP. 2000. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. AIDS Res. Hum. Retroviruses 16:517-528.
5. Balzarini J, et al. 1998. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 12:1129-1138.
6. Borkow G, et al. 1997. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71:3023-3030.
7. Brown BK, et al. 2005. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J. Virol. 79:6089-6101.
8. Buckheit RW, Jr, et al. 1997. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res. Hum. Retroviruses 13:789-796.
9. Buckheit RW, Jr, et al. 1997. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 41:831-837.
10. Damian F, Fabian J, Friend DR, Kiser PF. 2010. Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions. Int. J. Pharm. 396:1-10.
11. Derdeyn CA, et al. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
12. Dezzutti CS, et al. 2004. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 48:3834-3844.
13. Feldblum PJ, et al. 2008. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 3:e1474. doi:10.1371/journal.pone.0001474.
14. Friend DR. 2010. Pharmaceutical development of microbicide drug products. Pharm. Dev. Technol. 15:562-581.
15. Herold BC, Mesquita PM, Madan RP, Keller MJ. 2011. Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am. J. Reprod. Immunol. 65:325-333.
16. Keller MJ, et al. 2010. Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One 5:e8781. doi:10.1371/journal.pone.0008781.
17. McCormack S, et al. 2010. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376:1329-1337.
18. Neurath AR, Strick N, Li YY. 2006. Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides. BMC Infect. Dis. 6:150.
19. Njai HF, et al. 2005. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells. Antivir. Ther. 10:255-262.
20. Patton DL, et al. 2007. Preclinical safety assessments of UC781 antihuman immunodeficiency virus topical microbicide formulations. Antimicrob. Agents Chemother. 51:1608-1615.
21. Peterson L, et al. 2007. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2:e1312. doi:10.1371/journal.pone.0001312.
22. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
23. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
24. Rossi L. 28 September 2011, posting date. Microbicide Trials Network Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. Microbicide Trials Network.
25. Schwartz JL, et al. 2008. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex. Transm. Dis. 35:414-419.
26. Skoler-Karpoff S, et al. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987.
27. Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gamma-retroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82:12585-12588.
28. Van Damme L, et al. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977.
29. Van Herrewege Y, et al. 2004. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48:337-339.
30. Watson KM, Buckheit CE, Buckheit RW, Jr. 2008. Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay. Antimicrob. Agents Chemother. 52:2787-2796.
31. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.